Plain-English translation of NCT06757764 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After an acute ischemic stroke caused by narrowed arteries, doctors typically prescribe two blood-thinning medications: and . This trial is testing whether adding , a third blood-thinning medication, can further reduce the risk of having another stroke. Researchers believe this medication may be especially helpful for people whose stroke was caused by large artery atherosclerosis (narrowing of major blood vessels).
Even with the two standard blood-thinning medications, some patients still experience another stroke within weeks or months. This treatment gap is particularly common in people with large artery narrowing, so researchers want to know if adding the medication can prevent these early recurrent strokes.
You likely qualify if…
You likely don't qualify if…
You will randomly receive either the three-medication combination or two standard medications plus a placebo (inactive pill). You'll take for 21 days, then continue and either or placebo for 180 days (about 6 months). If you need a stent placed during treatment, additional may be added for 90 days. During this time, you'll have study visits to monitor your recovery and check for any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
South Korea